




The relative strengths and weaknesses of GT Biopharma Inc are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of GT Biopharma Inc compared to the market average is the variable Other Net Income, increasing the Economic Capital Ratio by 7.7% points. The greatest weakness of GT Biopharma Inc is the variable Stockholders Equity, reducing the Economic Capital Ratio by 79% points.

The company's Economic Capital Ratio, given in the ranking table, is 59%, being 156% points below the market average of 215%.

Input Variable	Value in 1000 USD
Assets, Current	4,232
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	5,902
Liabilities, Non-Current	0
Other Assets	0
Other Compr. Net Income	0
Other Expenses	0
Other Liabilities	0
Other Net Income	1,202
Other Revenues	0
Property and Equipment	0
Research and Development	5,798
Selling, General and Administrative Expense	8,566

Output Variable	Value in 1000 USD
Assets	4,232
Liabilities	5,902
Expenses	14,364
Revenues	0
Stockholders Equity	-1,670
Net Income	-13,162
Comprehensive Net Income	-13,162
BaseVar	12,850
ECR before LimitedLiability	-332%
Economic Capital Ratio	59%